Substance,Type of TRV,TRV Value,Study Details,"Threshold/
Non-threshold
Endpoint",TRV Derivation Method,"Critical
Effect(s)","Carcinogenicity
Classification",Source
"Benzo[a]pyrene
(BaP)",Inhalation TC,"2.0E-06
mg/m3","Study Type: developmental
Species: F344 rats (pregnant females)
Mode of Administration: inhalation
(nose only)
Exposure Regime: 0 (“sham” carbon
black or unexposed), 25, 75, and
100 µg/m3, 4 hours per day for 10 days
(gestation days 11 to 20)
Duration: 10 days (gestation days 11-20)
Uncertainty Factors: 3000 (3 for
toxicodynamic differences, 10 for
intraspecies variability, 10 for LOAEL
to NOAEL extrapolation, and 10
for database deficiencies)","LOAEL =
0.025 mg/m3","LOAEL adjusted for
continuous daily exposure
and converted to a human
equivalent concentration
based on a regional
deposited dose ratio for
extrarespiratory effects
LOAEL =
HEC
0.0046 mg/m3
RfC = LOAEL /UF
HEC","Developmental
toxicity
(decreased
embryo/foetal
survival)","CEPA: Group II
probably
carcinogenic
to humans
(EC and HC, 1994a)
IARC: Group 1
carcinogenic
to humans
(IARC, 2012b)
US EPA
carcinogenic
to humans
(US EPA, 2017)","US EPA, 2017
(based on
Archibong et al.,
2002)"
"Benzo[a]pyrene
(BaP)",Oral SF,"1.289E+00
(mg/kg -day) –1
BW","Study Type: chronic
Species: B6C3F1 female mice
Mode of Administration: diet
Exposure Regime: 0, 5, 25, and 100 ppm
(corresponding to approximately 0, 0.7,
3.3, and 13.0 mg/kg -day, as per HC,
BW
2016a)
Duration: 2 years
Uncertainty Factors: N/A","BMDL =
10
0.5389 mg/kg -day
BW","Allometric scaling of
the BMDL (to account
10
for interspecies variability
and derive a human
equivalent value)
BMDL =
10, HEC
0.07758 mg/kg -day
BW
Oral SF =
0.1/BMDL
10, HEC
where 0.1 = 10% extra
cancer risk","Digestive
tract toxicity
(tumours of the
forestomach)",,"HC, 2016a
(based on
Culp et al., 1998
and Moffat et al.,
2015)"
"Benzo[a]pyrene
(BaP)",Inhalation UR,"6.0E-01
(mg/m3)–1","Study Type: chronic
Species: Syrian golden male hamsters
Mode of Administration: inhalation
(nose only) of benzo[a]pyrene condensed
onto sodium chloride aerosols
Exposure Regime: 2.2, 9.5, and
46.5 mg BaP/m3 (time-weighted average
concentrations of 0, 0.25, 1.01, and
4.29 mg/m3, corresponding to 0, 2,
10, and 50 mg/m3 nominal study
concentrations), 4.5 hours/day for
the first 10 weeks, then 3 hours/day
for the remainder of the study
Duration: minimum of 10 weeks up
to 130 weeks
Uncertainty Factors: N/A","BMCL =
10
0.16 mg/m3","Multistage Weibull
time-to-tumour
dose-response model
+
Linear extrapolation from
the POD associated with
10% extra cancer risk
Inhalation UR =
0.1/BMCL
10
where 0.1 is 10% extra
cancer risk","Cancer
(tumours of
the upper
gastrointestinal
tract and upper
respiratory tract
[squamous cell
neoplasia in the
larynx, pharynx,
trachea, nasal
cavity, esophagus,
and forestomach])",,"US EPA, 2017
(based on
Thyssen et al.,
1981)"
